<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ther Ultrasound</journal-id><journal-id journal-id-type="iso-abbrev">J Ther Ultrasound</journal-id><journal-title-group><journal-title>Journal of Therapeutic Ultrasound</journal-title></journal-title-group><issn pub-type="epub">2050-5736</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4292024</article-id><article-id pub-id-type="publisher-id">2050-5736-2-S1-A17</article-id><article-id pub-id-type="doi">10.1186/2050-5736-2-S1-A17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Palliative treatment of bone metastases: analysis of biological effects of MR guided Focused Ultrasound (MRgFUS) versus External Beam Radiation Therapy (EBRT). A randomized comparative trial using Functional Diffusion Maps as molecular activity indicator</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Anzidei</surname><given-names>Michele</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>michele.anzidei@gmail.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Napoli</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Brachetti</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Del Monte</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>De Olivera</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Andrani</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Palla</surname><given-names>Carola</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Bertaccini</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Musio</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Tombolini</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Catalano</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Radiological Oncological and Pathological Sciences, &#x0201c;Sapienza&#x0201d;Unversity of Rome, Italy</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstracts of the 2nd European Symposium on Focused Ultrasound Therapy</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the Focused Ultrasound Foundation.</named-content></supplement><fpage>A17</fpage><lpage>A17</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Anzidei et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Anzidei et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.jtultrasound.com/content/2/S1/A17"/><conference><conf-date>10-11 October 2013</conf-date><conf-name>2nd European Symposium on Focused Ultrasound Therapy</conf-name><conf-loc>Rome, Italy</conf-loc></conference></article-meta></front><body><sec><title>Backgroud</title><p>New functional and metabolic imaging techniques may provide the ability to assess biological changes that act as indicators of therapy response [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Particularly, Diffusion-Weighted Imaging (DWI) can be used to monitor change in cellularity within the tumour over time, which is reflective of response to therapy [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Our study aims to investigate and compare the response to MR guided Focused Ultrasound (MRgFUS) and External Beam Radiation Therapy (EBRT) treatments of painful bone metastases by using DW Magnetic Resonance imaging (DW-MRI) with apparent diffusion coefficient (ADC).Furthermore, we analyzed the correlation between DW-MRI and the Visual Analogue Scale (VAS).</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This prospective, double arm, randomized study with EBRT serving as control arm, received IRB approval. 36 consecutive patients (female:15 male:21 mean age:60.3) with painful bone metastases were enrolled. 18 patients underwent MRgFUS treatment, using ExAblate 2100 system (InSightec), and 18 patients underwent EBRT. Pain palliation was evaluated by visual analog scale (VAS), pain questionnaires and changes in the patients&#x02019; medication. All patients underwent 3T ce-MRI (Discovery 750, GE; gd-BOPTA, Bracco) before treatment and at 1, 2, and 3 months afterward. MRI protocol included DWI sequences with five <italic>b</italic> factors (0&#x02013;800 s/mm<sup>2</sup>) and ADC were obtained. The average ADC values for each lesion were analyzed in comparison between pre- and post-treatment.</p></sec><sec sec-type="results"><title>Results</title><p>No treatment-related adverse events were recorded for both arms. Statistically significant difference between baseline and follow-up VAS values and medication intake for both MRgFUS and EBRT patients (p&#x0003c;0.05) was noted. DWI showed substantial increase in mean ADC values after treatment for both MRgFUS (pre:1080,6&#x000b1;269 mm&#x000b2;/s; post: 1577,5&#x000b1;311,6) and EBRT (pre:1313,3&#x000b1;424,3 mm&#x000b2;/s; post:1777,9&#x000b1;386,3); there were no significant statistical differences in ADC shift following between MRgFUS and ERBT (p&#x0003e;0.5). Progressive decrease in VAS values positively correlated to an increase in mean ADC values (p&#x0003e;0.01) for both treatment modalities (Tables <xref ref-type="table" rid="T1">1</xref>, <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><table frame="hsides" rules="groups"><thead><tr><th align="left">MRgFUS</th><th align="left">baseline</th><th align="left">Follow-up 1 month</th><th align="left">Follow-up 2 months</th><th align="left">Follow-up 3 months</th></tr></thead><tbody><tr><td align="left"><bold>ADC</bold></td><td align="left">1080.6&#x000b1;269 mm<sup>2</sup>/s</td><td align="left">1347.2&#x000b1;294 mm<sup>2</sup>/s</td><td align="left">1428.7&#x000b1;306.7 mm<sup>2</sup>/s</td><td align="left">1577.5&#x000b1;311.6 mm<sup>2</sup>/s</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left"><bold>VAS</bold></td><td align="left">7.09&#x000b1;1.8 (range 4-10)</td><td align="left">2.65&#x000b1;1.36 (range 0-5)</td><td align="left">1.04&#x000b1;1.91 (range 0-6)</td><td align="left">1.09&#x000b1;1.99 (range 0-6)</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><table frame="hsides" rules="groups"><thead><tr><th align="left">EBRT</th><th align="left">baseline</th><th align="left">Follow-up 1 month</th><th align="left">Follow-up 2 months</th><th align="left">Follow-up 3 months</th></tr></thead><tbody><tr><td align="left"><bold>ADC</bold></td><td align="left">1313.3&#x000b1;424.3mm<sup>2</sup>/s</td><td align="left">1463&#x000b1;361.7 mm<sup>2</sup>/s</td><td align="left">1611&#x000b1;373.2 mm<sup>2</sup>/s</td><td align="left">1777.9&#x000b1;386.3 mm<sup>2</sup>/s</td></tr><tr><td colspan="5"><hr/></td></tr><tr><td align="left"><bold>VAS</bold></td><td align="left">6.12&#x000b1;1.1 (range 5-10)</td><td align="left">3.51&#x000b1;1.54 (range 0-6)</td><td align="left">1.32&#x000b1;1.48 (range 0-4)</td><td align="left">1.02&#x000b1;1.36 (range 0-4)</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>DW-MRI with ADC is a viable option for assessing tumor response to MRgFUS therapy for bone metastases. The increase in mean ADC values of ablated bone metastases could reflect pathophysiologic alterations that occur after ablative therapy [<xref ref-type="bibr" rid="B6">6</xref>]. It is therefore possible that ADC variations could effectively describe and express effects on tumor mass control induced by focused ultrasound ablation. MRgFUS is a promising noninvasive treatment modality for successful palliation of bone metastasis [<xref ref-type="bibr" rid="B7">7</xref>] and has potential for tumor control (Figures <xref ref-type="fig" rid="F1">1</xref>, <xref ref-type="fig" rid="F2">2</xref>) [<xref ref-type="bibr" rid="B8">8</xref>] as compared to ERBT. MRgFUS determines bone metastasis cell damage similarly to EBRT as demonstrated by linear ADC modification.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>67 years old patient with lung cancer. MR images acquired before and after MR guided ultrasound treatment shows increase ADC value at 3 months follow-up (1878.33 mm<sup>2</sup>/s) compared to baseline (991.87 mm<sup>2</sup>/s). Also at the end of follow-up we observed absence of pain (VAS baseline: 7; VAS 3 months: 0).</p></caption><graphic xlink:href="2050-5736-2-S1-A17-1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>70 years old patient with renal cell carcinoma. Same as figure <xref ref-type="fig" rid="F1">1</xref>, it has been verified an increase ADC value after MR guided ultrasound treatment (ADC baseline: 1262 mm<sup>2</sup>/s. ADC 3 months: 1847 mm<sup>2</sup>/s). At 3 months follow-up VAS value 4 (VAS baseline 8).</p></caption><graphic xlink:href="2050-5736-2-S1-A17-2"/></fig></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Harry</surname><given-names>VN</given-names></name><etal/><article-title>Use of new imaging techniques to predict tumour response to therapy</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70190-1</pub-id><pub-id pub-id-type="pmid">20129132</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Vassiliou</surname><given-names>V</given-names></name><etal/><article-title>Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2011</year><volume>23</volume><issue>9</issue><fpage>632</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.clon.2011.03.010</pub-id><pub-id pub-id-type="pmid">21530193</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Charles-Edwards</surname><given-names>EM</given-names></name><etal/><article-title>Diffusion-weighted magnetic resonance imaging and its application to cancer</article-title><source>Cancer Imaging</source><year>2006</year><volume>6</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1102/1470-7330.2006.0021</pub-id><pub-id pub-id-type="pmid">17015238</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Reischauer</surname><given-names>C</given-names></name><etal/><article-title>Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps. Initial Observations</article-title><source>Radiology</source><year>2010</year><volume>257</volume><fpage>2</fpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Mardor</surname><given-names>Y</given-names></name><etal/><article-title>Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>6</issue><fpage>1094</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.05.069</pub-id><pub-id pub-id-type="pmid">12637476</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>NB</given-names></name><etal/><article-title>Thermal effects of focused ultrasound energy on bone tissue</article-title><source>Ultrasound Med Biol</source><year>2001</year><volume>27</volume><issue>10</issue><fpage>1427</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0301-5629(01)00454-9</pub-id><pub-id pub-id-type="pmid">11731056</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Napoli</surname><given-names>A</given-names></name><name><surname>Anzidei</surname><given-names>M</given-names></name><name><surname>Marincola</surname><given-names>BC</given-names></name><name><surname>Brachetti</surname><given-names>G</given-names></name><name><surname>Noce</surname><given-names>V</given-names></name><name><surname>Boni</surname><given-names>F</given-names></name><name><surname>Bertaccini</surname><given-names>L</given-names></name><name><surname>Passariello</surname><given-names>R</given-names></name><name><surname>Catalano</surname><given-names>C</given-names></name><article-title>MR Imaging-guided Focused Ultrasound for Treatment of Bone Metastasis</article-title><source>Radiographics</source><year>2013</year><volume>33</volume><issue>6</issue><fpage>1555</fpage><lpage>68</lpage><comment>doi: 10.1148/rg.336125162</comment><pub-id pub-id-type="doi">10.1148/rg.336125162</pub-id><pub-id pub-id-type="pmid">24108551</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Napoli</surname><given-names>A</given-names></name><name><surname>Anzidei</surname><given-names>M</given-names></name><name><surname>Marincola</surname><given-names>BC</given-names></name><name><surname>Brachetti</surname><given-names>G</given-names></name><name><surname>Ciolina</surname><given-names>F</given-names></name><name><surname>Cartocci</surname><given-names>G</given-names></name><name><surname>Marsecano</surname><given-names>C</given-names></name><name><surname>Zaccagna</surname><given-names>F</given-names></name><name><surname>Marchetti</surname><given-names>L</given-names></name><name><surname>Cortesi</surname><given-names>E</given-names></name><name><surname>Catalano</surname><given-names>C</given-names></name><article-title>Primary pain palliation and local tumor control in bone metastases treated with magnetic resonance-guided focused ultrasound</article-title><source>Invest Radiol</source><year>2013</year><volume>48</volume><issue>6</issue><fpage>351</fpage><lpage>8</lpage><comment>doi: 10.1097/RLI.0b013e318285bbab</comment><pub-id pub-id-type="doi">10.1097/RLI.0b013e318285bbab</pub-id><pub-id pub-id-type="pmid">23571832</pub-id></mixed-citation></ref></ref-list></back></article>